• Text size
  • Send this article to a friend
  • Print this article

ProStrakan still expects US approval for cancer drug

SHARES in ProStrakan yesterday slipped almost 3% after the Borders-based specialist drug company revealed that the US Food and Drug Administration had missed the deadline for action on Sancuso, the company's cancer treatment.

Custom byline text: 
MARK SMITH, Deputy Business Editor

SHARES in ProStrakan yesterday slipped almost 3% after the Borders-based specialist drug company revealed that the US Food and Drug Administration had missed the deadline for action on Sancuso, the company's cancer treatment.